Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026

Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ:...

Company Drug

Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients

Fineline Cube Aug 5, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s New...

Company Drug

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Fineline Cube Aug 5, 2026

Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application...

Company Drug PIC

Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age

Fineline Cube Aug 5, 2026

Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has approved an extension of the...

Company PIC

Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring

Fineline Cube Aug 5, 2026

Novo Nordisk (NYSE: NVO) today released its financial results for the second quarter of 2026,...

Company Drug

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

Fineline Cube Aug 5, 2026

Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name:...

Company PIC

Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year

Fineline Cube Aug 5, 2026

Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026,...

Company PIC

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

Fineline Cube Aug 5, 2026

AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance...

Company PIC

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Fineline Cube Aug 5, 2026

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) released its first-half 2026 (H1’2026) financial results....

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026

Alphamab Oncology (HKG: 9966) announced that it has entered into a licensing agreement with Pathos...

Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026

In May 2026, Hunan Zonsen PepLib Biotech Inc. successfully completed a Series C financing round...

Company Drug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 5, 2026

CARsgen Therapeutics (HKG: 2171) announced that CT0596 has received clinical approval from the National Medical...

Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the combination regimen of orelabrutinib and...

Company Drug

Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC

Fineline Cube Aug 5, 2026

Adlai Nortye (NASDAQ: ANL) announced that the company’s independently developed antibody-drug conjugate (ADC) AN4035, which...

Company Drug

Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma

Fineline Cube Aug 4, 2026

Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced that the US Food and Drug Administration (FDA)...

Drug

FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States

Fineline Cube Aug 4, 2026

On July 29, 2026, the U.S. FDA granted a biologics license to Ezplaz Freeze Dried...

Company Drug

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

Fineline Cube Aug 4, 2026

Novartis (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto...

Company PIC

HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline

Fineline Cube Aug 4, 2026

HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced its financial results for the six months...

Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026

Siemens Healthineers AG (ETR: SHL) and Cleveland Clinic announced the signing of a 10-year strategic...

Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026

Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) announced that it has signed a Strategic Cooperation Framework...

Posts pagination

1 … 14 15 16 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.